This site is intended only for all Healthcare Professionals residing in South Africa




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer medical information



Dosage Efficacy Indications Multimodal approach to post-operative pain Prescribing Information Safety and Tolerability Safety Information
Safety and TolerabilityRAYZON® (parecoxib sodium) – Well-tolerated with decreased risk of gastroduodenal mucosal injury vs ketorolac1

COX-2 inhibitors have analgesic efficacy comparable with that of conventional nonsteroidal anti-inflammatory drugs (NSAIDs) and may be associated with reduced gastrointestinal (GI) side effects compared with conventional NSAIDs1,2

RAYZON® (parecoxib sodium) has significantly (p<0.05) lower incidence of upper GI ulceration and/or erosion vs. ketorolac1Indications

* Significantly different from both other treatments, p<0.05

Two-center, double-blind, randomized, placebo-controlled study of healthy 65-75 year-old subjects (n=94) whose baseline endoscopy showed no gastric or duodenal lesions given either parecoxib sodium 40 mg b.i.d. for 7 days, ketorolac 15 mg q.i.d. for 5 days, or placebo for 7 days1

RAYZON® (parecoxib sodium) – Less likely to be associated with excessive bleeding during surgery3

RAYZON® (parecoxib sodium) (40 mg BID) demonstrated little to no effect on platelet aggregation while ketorolac (30 mg QID) significantly decreases aggregation3

Platelet response to arachidonate at baseline and on last drug administration day in elderly individuals. Statistical comparisons are based on changes from baseline:3
* indicated p<0.001 for change from vs ketorolac;
** indicated p<0.001 for changes from baseline vs placebo. None of the differences between parecoxib sodium and placebo were statistically significant


The study of elderly participants was a single centre, double-blind, randomised, active- and placebo-controlled, parallel-group comparison of parecoxib sodium 10 mg twice daily intravenously. parecoxib sodium 40 mg twice daily intravenously, ketorolac 15 mg four times daily intravenously (the recommended dosage for patients over the age of 65 years) or placebo3

Abbreviations:BID: twice daily; GI: gastrointestinal; IV: intravenously; QID: four times daily.ReferencesStoltz RR, Harris SI, Kruss ME, et al. Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. Am. J. Gastroenterol. 2002;97(1):65-71.Gajraj NM. Cyclooxygenase-2 inhibitors. Anesthesia & Analgesia. 2003;96(6):1720-38.Noveck RJ, Richard C. Parecoxib Sodium does not impair platelet function in healthy elderly and non-elderly individuals: two randomised, controlled trials. Clin Drug Invest. 2001;21(7):465-76.
Support & Services

Copyright ©2024 Pfizer South Africa All rights reserved.

  • The information contained herein is provided for educational purposes only and is not intended to constitute medical advice or replace discussions with a Healthcare Professional. All decisions regarding patient care must be made with a Healthcare Professional, considering the unique characteristics of the patient.
  • While every effort is made to update the information regularly and to offer the most current, correct and clearly expressed information possible, Pfizer cannot be held responsible for any inaccuracy, errors, omissions or misinterpretations.
  • Pfizer, its officers and/or its employees do not accept or take any responsibility whatsoever for any loss, whether direct, indirect or consequential, which may arise from reliance on information contained on these pages and actions resulting therefrom. Any liability that would or could arise as a result of the contents of these pages is hereby excluded to the fullest extent allowed by law.
  • No warranty is given that any files, downloads or applications available via this web site are free of viruses which have the ability to corrupt your system.
  • Any and all information is subject to change without notice.
  • The information provided in this site is intended only for appropriate Healthcare Professionals residing in South Africa.


PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for all Healthcare Professionals residing in South Africa. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer South Africa 

Pfizer Laboratories (Pty) Ltd. Company Reg. No. 1954/000781/07. Building 2, 1st Floor, Maxwell Office Park, Magwa Crescent, Waterfall City, Midrand, Johannesburg, South Africa. Tel. No: 0860 PFIZER (734937).


Copyright © 2024. Pfizer Laboratories (Pty) Ltd. All rights reserved

For South Africa Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional webpages contain promotional content.

I confirm that I am a healthcare professional residing in South Africa. If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

Yes No
You are now leaving the PfizerPro South Africa website
You are leaving the South Africa HCP Portal website and being directed to a new website

This website is not controlled by South Africa HCP portal or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable
You are now leaving PfizerPro You are now leaving PfizerPro and will be directed to our provider to complete your registration. Any personal information that you may find prepopulated from your PfizerPro profile, or you may provide, will be governed by Privacy Policy. Your data will not be used for any other purpose.